ArticleInflammopharmacology2025
Targeted suppression of cytokine-mediated inflammation in rheumatoid arthritis by Melia azedarach L. extract.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Inflammation is a critical contributor to the pathogenesis of rheumatoid arthritis (RA), primarily mediated by NF-κB signalling. Medicinal plants have long been utilised for the treatment of inflammatory disorders, including RA, due to their minimal side effects and cost effectiveness. The current study was designed to explore the anti-inflammatory potential of Melia azedarach L. and to validate its traditional use in rheumatic disorders. Ethanolic extract of Melia azedarach (Ma.EE) was prepared and characterized by GCMS and FTIR techniques. Phytochemicals presents in the Ma.EE were quantified and extract was screened for free radical scavenging potential in in vitro antioxidant assays (DPPH and CUPRAC). Different doses Ma.EE (100, 200 and 400 mg/kg) were tested in acute inflammatory (carrageenan, serotonin and histamine-induced paw oedema) and CFA-induced arthritic models. qPCR analysis were performed to investigate the potential underlying mechanisms of inflammation reduction. GC-MS analysis confirmed the presence of anti-inflammatory compounds including oleic and erucic acid in Ma.EE and quantitative assays revealed high flavonoid (236.20 ± 12.09 mg QE/g DE), phenolic (34.66 ± 1.56 mg GAE/g DE), tannin (79.86 ± 26.73 mg TAE/g DE), and saponin (27.2%) contents. In vivo studies showed that Ma.EE (100, 200, 400 mg/kg) significantly (p < 0.001) attenuated paw oedema, particularly at 200 and 400 mg/kg. In the chronic model of paw inflammation, sustained reduction in paw volume was observed along with down-regulated (p < 0.001) mRNA expression of NF-κB, TNF-α, IL-1β, COX-2, and up-regulation of IL-10 respectively. Biochemical assessments showed decreased ALT and AST levels, while radiographic and histopathological analyses confirmed reduced joint damage and neutrophil infiltration. These findings suggest that Ma.EE exerts potent anti-inflammatory effects by modulating the NF-κB and COX-2 regulated cellular and molecular interactions.
Indexed as
Identifiers
41225149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.